Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222732 | 0.86 | HTR7 (0.48) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2222698 | 0.86 | KDM4E (0.45) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12517250 | 0.85 | KMT2A (0.47) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15678972 | 0.85 | MAPT (0.42) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15678973 | 0.85 | LMNA (0.48) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14554259 | 0.85 | KMT2A (0.46) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2225464 | 0.84 | TSHR (0.47) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14554261 | 0.84 | NPC1 (0.50) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL2223874 | 0.84 | DRD4 (0.44) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2224235 | 0.83 | HTR7 (0.47) | MEN1KMT2AKDM4EALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729149-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2014-05-14 | — | — | EP | claimed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | claimed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | claimed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | claimed |
| CN-102802627-A | Voltage-gated sodium channel blockers | GLAXO GROUP LTD | 2012-11-28 | — | — | CN | claimed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | claimed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | claimed |
| EP-2729149-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| CN-102802627-A | Voltage-gated sodium channel blockers | GLAXO GROUP LTD | 2012-11-28 | — | — | CN | disclosed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | MEN1 4275/4885KMT2A 2744/4885CYP1A2 1524/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | MEN1 3591/4885KMT2A 3151/4885CYP1A2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.